PDIGREE: An adaptive phase III trial of PD-inhibitor nivolumab and ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704).
Year: 2020
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Duke University, Duke Cancer Institute, Weill Cornell Medicine, Dana-Farber Cancer Institute, University of Kansas, Alliance for Clinical Trials in Oncology, University of Chicago, University of Illinois Chicago, Mayo Clinic, University of Wisconsin–Madison, The Barbara Ann Karmanos Cancer Institute, Memorial Sloan Kettering Cancer Center, Duke Medical Center, Harvard University, Dana-Farber/Harvard Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: National Institutes of Health
OpenAlex ID: W4239360448